Multiple Ascending Dose of BMS-911543

Exclusion Criteria

• •Primary central nervous system tumors
• •Subjects with currently active malignancy (other than MF) or with a prior history of malignancy with the exception of: (i) adequately treated basal cell carcinoma of the skin, (ii) curatively treated in situ carcinoma of the cervix, (iii) other malignancy that has undergone potentially curative therapy with no evidence of disease recurrence ≥3 years
• •Any condition requiring chronic use of moderate/high dose steroids except inhalation or oral steroids for mild pulmonary disease
• •Splenic irradiation ≤3 months prior to treatment with study drug
• •Positive blood screen for hepatitis C antibody, hepatitis B surface antigen or Human Immunodeficiency Virus-1 (HIV-1), or HIV-2 antibodies
• •Abnormalities in serum electrolytes
• •Significant cardiovascular disease
• •Current or recent gastrointestinal disease
• •Previous history of pancreatitis and/or significant risk factors for pancreatitis as judged by the treating physician
• •Evidence of uncontrolled active infection or active graft vs. host disease
• •Inability to tolerate oral medication